FDA Drastically Cuts CAMZYOS Heart Drug Monitoring Requirements: What This Means for 15,000+ Patients

FDA Updates Mavacamten Label in Obstructive Hypertrophic Cardiomyopathy

Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.

Label update expands Camzyos reach in obstructive HCM

The FDA has approved a sweeping label update for Bristol Myers Squibb’s Camzyos (mavacamten), the first‑and‑only FDA‑approved cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Until Camzyos reached the market in 2022, physicians mainly relied on beta‑blockers, calcium‑channel blockers, disopyramide or invasive septal‑reduction surgery to relieve outflow obstruction. The latest update lets… The p…

FDA Drastically Cuts CAMZYOS Heart Drug Monitoring Requirements: What This Means for 15,000+ Patients

New FDA update reduces CAMZYOS monitoring from 12 weeks to 6 months, expands patient eligibility. Real-world safety data from 15,000+ patients. See full changes.